Scholars Central

Conference abstractPublished 21 Oct 2013

Preclinical and clinical testing of a alpha-ketoglutarate/5-HMF/N-actyl-selenomethionine and N-acteyl-methionine for treating tumors

Authors: Joachim Greilberger

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

This lecture will address of the use of a newly developed therapeutic substance combination (KARAL®) namely alpha-ketoglutarate (AKG)/5-Hydroxymethylfurfurale (5-HMF)/N-Acetyl-Selenomethionine (NASeLM) and N-Acteyl-methionine (NALM). Supplementation of of AKG/5-HMF alone (Sanopal®, CYL-Phamraceutica) was used in a clinical study as pre-operative solution in patients with lung cancer. Results showed significant reduction of complications during surgery, massive better conditions before and after surgery (reduction of hospitalization +/- 11 days) compared to control group. Single substances, and combination of all substances in several concentrations showed on cancer cells (Jurkat, non-small cancer cells, thyroid cancer cells, prostate cancer cells) concentration dependent decrease of mitochondrial activity, cell growth and an increase of caspase-3 activity. In two pre-clinical studies (cancer in lung, pleura and esophagus and prostate cancer) on the Medical University of Graz and on the Medical University of Vienna promising results ratify the outcomes of cell studies.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Joachim Greilberger”